Key result
SLS-based decellularization combined with EDC/NHS crosslinking mitigated immune response and reduced calcification compared with glutaraldehyde treatment after 30 days of subcutaneous implantation.
Why the study?
Bioprosthetic heart valves inevitably undergo calcification and deterioration within 10-15 years, presenting a major clinical challenge.
Does SLS-based decellularization combined with EDC/NHS crosslinking reduce calcification and improve biocompatibility of bioprosthetic heart valves compared to glutaraldehyde treatment?
Does SLS-based decellularization combined with EDC/NHS crosslinking reduce calcification and improve biocompatibility of bioprosthetic heart valves compared to glutaraldehyde treatment?
A novel SLS-based decellularization and EDC/NHS crosslinking method for bioprosthetic heart valves reduces calcification and improves biocompatibility compared to standard glutaraldehyde treatment in preclinical models.
Currently, valve replacement surgery is the only therapy for the end-stage valvular diseases because of the inability of regeneration for diseased heart valves. Bioprosthetic heart valves (BHVs), which are mainly derived from glutaraldehyde (GA) crosslinked porcine aortic heart valves or bovine pericardium, have been widely used in the last decades. However, it is inevitable that calcification and deterioration may occur within 10–15 years, which are still the main challenges for the BHVs in clinic. In this study, N-Lauroylsarcosine sodium salt (SLS) combined with N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS) were utilized to decellularize and crosslink the heart valves instead of GA treatment. The obtained BHVs exhibited excellent extracellular matrix stability and mechanical properties, which were similar with GA treatment. Moreover, the obtained BHVs exhibited better in vitro biocompatibilities than GA treatment. After subcutaneous implantation for 30 d, the obtained BHVs showed mitigated immune response and reduced calcification compare with GA treatment. Therefore, all the above results indicated that the treatment of SLS-based decellularization combined with EDC/NHS crosslink should be a promising method to fabricate BHVs which can be used in clinic in future.
No takes yet. Share an insight, caveat, or question.
Luo et al. (2021) studied end-stage valvular diseases. SLS-based decellularization combined with EDC/NHS crosslinking vs. Glutaraldehyde (GA) treatment was evaluated on Extracellular matrix stability, mechanical properties, biocompatibility, immune response, and calcification. SLS-based decellularization combined with EDC/NHS crosslinking mitigated immune response and reduced calcification compared with glutaraldehyde treatment after 30 days of subcutaneous implantation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: